{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.51","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.98"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"33.4","value":"15.9"},{"groupId":"OG001","lowerLimit":"15.4","upperLimit":"23","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 90% confidence interval.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients received single-agent Nivolumab IV","id":"OG000","title":"Part B Arm 1 (Nivolumab)"},{"description":"Patients received combination Nivolumab and Ipilimumab IV","id":"OG001","title":"Part B Arm II (Nivolumab, Ipilimumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initiation of treatment until death, assessed up to 2 years","title":"Overall Survival (Part B)","type":"SECONDARY","unitOfMeasure":"months"}